Review of tarlatamab for solid tumors and small cell lung cancer

People with solid tumors and small cell lung cancer need new options. This review looks at tarlatamab, a type of T cell engager. These drugs help the immune system fight cancer cells. The text explains what T cell engagers are and how they function in the body. It covers the specific conditions this medication targets. The review does not report specific patient numbers or exact results. It notes that safety data and tolerability were not reported in the source. The study type is a review, meaning it gathers existing information. Readers should know the evidence details are limited by the source. This approach helps understand the potential role of these treatments. The narrative stays grounded in what the source actually provides. It avoids making claims about cures or breakthroughs that are not supported. The focus remains on the mechanism and the conditions listed.